Publications
The economic burden of overweight and obesity in Europe
24 September 2026
Effective obesity strategies require action across government and society, and a broader approach to evaluating their costs and benefits.
Unlocking the broader value of biologic therapies through biosimilar-enabled access and repositioning
23 September 2026
Biologic medicines account for over 40% of global pharmaceutical spend. When originator patents expire, biosimilar competition should drive prices down, generating cost-savings, broadening access, and improving…
Addressing the systemic challenges of underinvestment in prevention
8 June 2026
Prevention of ill-health is an underexploited tool for protecting health systems and societies. It offers the potential to curb increasing demand for healthcare services, increase participation…
The impact of inflation on incremental costs in HTA
4 June 2026
Inflation reshapes the economic landscape in which new treatments are evaluated. Yet cost-effectiveness thresholds tend to remain fixed over time. This report examines how inflation in…
The value of fast diagnostics in time-critical infections
20 April 2026
Advancing earlier intervention in time‑critical infections Sepsis continues to impose a substantial global burden, with millions of cases and high mortality each year. Patients with bloodstream…
Evaluating novel antimicrobials within EU joint clinical assessments
16 April 2026
Antimicrobial resistance (AMR) is a growing global health and economic threat. It is responsible for an additional 9.5 million hospital days and costs across the European Union (EU) and European Economic Area (EEA) economies €11.7 billion annually.
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
31 March 2026
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally, and is responsible for substantial health and economic burden to health systems and wider society.
The case for adopting a broader perspective on value in Health Technology Assessment
3 March 2026
In this Whitepaper, we describe different perspectives that can be adopted in Health Technology Assessment (HTA), and some of the advantages and disadvantages of these different…
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
Biologics: Driving innovation in the treatment of multiple myeloma Biological medicines (biologics) have transformed the treatment landscape of multiple myeloma and cancer as a whole. The…